---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-098423"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:11:31.613841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mirum reports preliminary Q1 2023 revenue of $31.5M, cash $232.1M; updates VISTAS trial timeline

## Summary
- Preliminary Q1 2023 total revenue ~$31.5M, product sales net ~$29M, license revenue ~$2.5M.
- Cash, cash equivalents and short-term investments ~$232.1M as of March 31, 2023.
- Operating expenses consistent to moderately increased versus Q4 2022.
- VISTAS Phase 2b (volixibat in PSC) blinded interim analysis now expected H2 2023.
- VANTAGE Phase 2b (PBC) interim and EMBARK Phase 2b (biliary atresia) topline data remain on track for H2 2023.

## SEC filing metadata
- accession: 0001193125-23-098423
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/0001193125-23-098423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/d442377d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-098423
- JSON: https://secwatch.observer/filing/0001193125-23-098423.json
- Plain text: https://secwatch.observer/filing/0001193125-23-098423.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported first quarter of 2023 results: revenue approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro.
  - Period: first quarter of 2023
  - Revenue: approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro
  - Result: preliminary results
  source text: The company’s preliminary unaudited financial results for the first quarter of 2023 include: • Approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and approximately $2.5 million of license revenue, for the three months ended March 31, 2023;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/0001193125-23-098423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.